3rd Quarter - Report
FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC
Client
Income
—
Expenses
$75,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY | Congressman John Tierney Senator Tom Carper |
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
Pharmacy PHA
Rebate reform, any willing pharmacy, PBMs, IRA Medicare Direct Negotiation, DIR fees
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY | Congressman John Tierney Senator Tom Carper |
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
Medicare/Medicaid MMM
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY | Congressman John Tierney Senator Tom Carper |
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
Taxation/Internal Revenue Code TAX
Tax incentives for American production of pharmaceutical product, opioid taxes
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY | Congressman John Tierney Senator Tom Carper |
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.